CMAB, a comprehensive biomedicine business service supplier in BioBay, signed an agreement with SIP-based pharmaceutical company Qide Medical Science & Technology (Suzhou) Co Ltd on June 5 to launch strategic cooperation in development of antitumor drugs.

As a CDMO (contract development and manufacturing organization), namely a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug discovery through drug manufacturing, CMAB will provide Qide with one-stop services for medicine research, clinical trial, mass production and domestic and overseas application for related permits. Its services will help the company put their new drugs into the market at a lower cost and faster speed.